Inovio Pharmaceuticals investors face class action over alleged regulatory pathway misrepresentations.

miércoles, 4 de marzo de 2026, 9:03 am ET1 min de lectura
INO--

A securities class action has been filed against Inovio Pharmaceuticals, alleging misrepresentations about its regulatory pathway eligibility. Investors who purchased INO securities between October 10, 2023, and December 26, 2025, have until April 7, 2026, to seek lead plaintiff status.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios